Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Adropin is a secreted protein that regulates endothelial function. However, adropin levels in obese adolescent patients are currently uncertain. Therefore, we evaluated the association between plasma adropin levels and vascular endothelial function and investigated the effect of aerobic exercise in obese adolescents. A total of 45 obese adolescents and 20 controls (age 16-19 years) were included in our study. The obese adolescents received 12 weeks of aerobic exercise training. Serum adropin was detected using enzyme-linked immunosorbent assay. Vascular reactive hyperemia indexes (RHIs) were obtained using Endo-PAT2000. Adropin levels and RHI were significantly lower in obese adolescents than in normal-weight adolescents. Adropin levels and RHI increased significantly independently of changes in body weight after an exercise intervention (P < 0.01). Pearson correlation analysis revealed that adropin levels positively correlated with HDL-C levels (r = 0.389, P < 0.01) and RHI (r = 0.32, P < 0.01). Multiple linear stepwise regression analysis showed that the insulin resistance index (t = -3.301, P < 0.01) and HDL-C level (t = 2.620, P = 0.011) were independent risk factors of adropin levels. In addition, Δadropin (t = 3.261, P < 0.01) was an independent influencing factor of ΔRHI. Our findings suggest that adropin plays an important role in vascular endothelial function in obese adolescents.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735148 | PMC |
| http://dx.doi.org/10.1038/s41598-017-18086-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of a Specific Competitive ELISA for Plasma Adropin Levels and Its Application to Investigating Energy Homeostasis in Mice.
Biol Pharm Bull
September 2025
Laboratory of Epidemiology and Prevention, Kobe Pharmaceutical University, Kobe 685-8558, Japan.
Adropin is a 43-amino acid peptide that is highly conserved among mammals. First identified in the mouse liver in 2008, adropin is broadly expressed throughout the body and has been implicated in various pathological conditions, including obesity, altered food intake, insulin resistance, glucose intolerance, and other disorders related to energy metabolism. However, its precise physiological role remains unclear.
View Article and Find Full Text PDFAdropin as a therapeutic candidate for HFpEF: evidence of oxidative stress mitigation via Nrf2/HO-1 signaling.
Lipids Health Dis
September 2025
Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Background: Heart failure with preserved ejection fraction (HFpEF), which accounts for more than half of all heart failure cases worldwide, has emerged as a major public health challenge characterized by substantial morbidity and mortality rates. As adropin is a key regulator of cardiovascular and metabolic homeostasis, this study investigated its therapeutic effects against HFpEF pathogenesis.
Methods: C57BL/6 mice were fed a high-fat diet (60% fat-derived calories) with NG-nitro-L-arginine methyl ester (L-NAME, 0.
The Association of Adropin with Asymptomatic Coronary Calcification in Patients in Early Stages of Chronic Kidney Disease.
Int J Mol Sci
August 2025
Department of Internal Medicine and Nephrology, VitaCenter, 69000 Zaporozhye, Ukraine.
Early stages of chronic kidney disease (CKD) are closely associated with vascular remodeling and coronary artery calcification. The aim of this study is to determine whether adropin is associated with asymptomatic coronary calcification in patients in the early stages of CKD. This study enrolled 337 individuals fulfilling the inclusion criteria of the early stages of CKD (G1-2, A1-3) and divided them into two subgroups with ( = 196) and without ( = 141) asymptomatic coronary artery calcification.
View Article and Find Full Text PDFLow Levels of Adropin Predicted New Incidents of Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction.
Biomolecules
August 2025
Department of Internal Medicine II, Division of Cardiology, Paracelsus Medical University, 5020 Salzburg, Austria.
Background: Atrial fibrillation (AF) is common complication of heart failure with preserved ejection fraction (HFpEF) that sufficiently intervenes in the prognosis. The aim of the study is a) to investigate the possible discriminative value of adropin for newly onset AF in patients with HFpEF without a previous history of AF and who are being treated in accordance with conventional guideline and b) to compare it with predictive potencies of conventionally used predictors.
Methods: A total of 953 patients with HFpEF who had sinus rhythm on ECG were enrolled in the study.
Clinical Significance of Adropin and Salusins Circulating Levels in End-Stage Kidney Disease Patients With Cardiovascular Events.
Hemodial Int
August 2025
Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.
Introduction: Patients with end-stage kidney disease (ESKD) face a significantly increased risk of cardiovascular disease (CVD). Effective management of these patients necessitates the early identification and continuous monitoring of cardiovascular complications. This study aimed to evaluate the clinical utility of circulating adropin, salusin-α (Sal-α), and salusin-β (Sal-β) levels in ESKD patients, with and without co-occurring CVD.
View Article and Find Full Text PDF